IRIS
TARANTINO, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.829
NA - Nord America 4.132
EU - Europa 3.008
SA - Sud America 573
AF - Africa 122
OC - Oceania 7
AN - Antartide 1
Totale 12.672
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.965
SG - Singapore 2.116
RU - Federazione Russa 1.592
VN - Vietnam 980
CN - Cina 879
BR - Brasile 461
HK - Hong Kong 407
IT - Italia 280
DE - Germania 233
FI - Finlandia 194
NL - Olanda 164
FR - Francia 142
IE - Irlanda 101
CA - Canada 95
GB - Regno Unito 84
JP - Giappone 81
UA - Ucraina 71
IN - India 70
SE - Svezia 54
MX - Messico 47
AR - Argentina 42
BD - Bangladesh 42
ZA - Sudafrica 38
CI - Costa d'Avorio 36
PH - Filippine 36
PL - Polonia 29
TH - Thailandia 29
IQ - Iraq 27
KR - Corea 23
TR - Turchia 23
ES - Italia 21
EC - Ecuador 19
ID - Indonesia 18
PK - Pakistan 17
UZ - Uzbekistan 13
AT - Austria 10
CO - Colombia 10
CL - Cile 9
MA - Marocco 9
PY - Paraguay 9
TW - Taiwan 9
JO - Giordania 8
LT - Lituania 8
SA - Arabia Saudita 8
UY - Uruguay 8
KE - Kenya 7
VE - Venezuela 7
AZ - Azerbaigian 6
AE - Emirati Arabi Uniti 5
AU - Australia 4
BE - Belgio 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
JM - Giamaica 4
MY - Malesia 4
NP - Nepal 4
PE - Perù 4
TN - Tunisia 4
AO - Angola 3
BO - Bolivia 3
EG - Egitto 3
GN - Guinea 3
GR - Grecia 3
IR - Iran 3
PA - Panama 3
RS - Serbia 3
AF - Afghanistan, Repubblica islamica di 2
BB - Barbados 2
BW - Botswana 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
IL - Israele 2
KH - Cambogia 2
LK - Sri Lanka 2
MG - Madagascar 2
MN - Mongolia 2
NG - Nigeria 2
OM - Oman 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
CD - Congo 1
CG - Congo 1
CH - Svizzera 1
DZ - Algeria 1
GF - Guiana Francese 1
GM - Gambi 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
HU - Ungheria 1
KG - Kirghizistan 1
Totale 12.653
Salva come PNG Salva come JPEG
Città #
Singapore 959
San Jose 616
Hong Kong 387
Moscow 383
Chandler 314
Ashburn 287
Beijing 266
Ho Chi Minh City 263
Hanoi 233
Santa Clara 196
Amsterdam 143
The Dalles 141
Los Angeles 127
Princeton 113
Lauterbourg 107
Jacksonville 98
Millbury 95
Nanjing 83
Boston 82
Munich 79
New York 79
Council Bluffs 78
Tokyo 69
Napoli 67
Hefei 58
São Paulo 56
Buffalo 55
Naples 54
Des Moines 47
Dong Ket 44
Da Nang 40
Redondo Beach 40
Wilmington 39
Dallas 38
Helsinki 37
Haiphong 36
Orem 36
Turku 35
Ottawa 33
Brooklyn 32
Nanchang 29
Seattle 28
Boardman 25
Johannesburg 24
Chicago 23
Shenyang 21
Montreal 20
Warsaw 20
Hebei 19
London 19
Mexico City 19
Biên Hòa 18
Chennai 18
Falkenstein 18
Frankfurt am Main 18
Atlanta 17
Denver 16
San Francisco 16
Toronto 16
Nuremberg 15
Stockholm 15
Norwalk 14
Poplar 14
Changsha 13
Hải Dương 13
Rio de Janeiro 13
Tianjin 13
Ankara 12
Houston 12
Jiaxing 12
Phoenix 12
Rome 12
Tashkent 12
Bangkok 11
Belo Horizonte 11
Kunming 11
Milan 11
Campinas 10
Lahore 10
Ninh Bình 10
Thái Bình 10
Curitiba 9
Falls Church 9
Kronberg 9
Baghdad 8
Brasília 8
Dhaka 8
Guayaquil 8
Jakarta 8
Lawrence 8
Malmo 8
Memphis 8
Porto Alegre 8
Quito 8
Quận Bình Thạnh 8
Seoul 8
Shanghai 8
Bắc Giang 7
Dearborn 7
Dublin 7
Totale 6.747
Salva come PNG Salva come JPEG
Nome #
"obesity paradox" or "metabolically benign obesity"? 193
A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer 180
Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: a cross-sectional study on adult male population. 175
EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. 161
Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study 158
BISPHENOL A IN POLYCYSTIC OVARY SYNDROME AND ITS ASSOCIATION WITH LIVER-SPLEEN AXIS. 151
Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease 149
Quantification of sirolimus and everolimus by immunoassay techniques: test specificity and cross-reactivity evaluation 145
Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study 142
A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. 141
Hematocrit Values Predict Carotid Intimal-Media Thickness in Obese Patients With Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study 141
Incidence of hypertension in individuals with different blood pressure salt-sensitivity: results of a 15-year follow-up study. 140
Long-term assessment of plasma lipids in transplant recipients treated with tacrolimus in relation to fatty liver. 140
Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins. 137
ARE HEPATIC STEATOSIS AND CAROTID INTIMA MEDIA THICKNESS ASSOCIATED IN OBESE PATIENTS WITH NORMAL OR SLIGHTLY ELEVATED GAMMA-GLUTAMYL-TRANSFERASE? 135
A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient 134
Stability of sirolimus and everolimus measured by immunoassay techniques in whole blood samples from kidney transplant patients 134
Absence of pharmacokinetic interference of moxifloxacin on cyclosporine and tacrolimus in kidney transplant recipients 134
Exaggerated immune reactions predict the outcome of interferon therapy in patients with chronic hepatitis C. 133
Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. 133
The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome. 132
Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? 130
Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors 130
Sublingual administration improves systemic exposure of tacrolimus in kidney transplant recipients: comparison with oral administration 129
Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. 128
Circulating levels of sirtuin 4, a potential marker of oxidative metabolism, related to coronary artery disease in obese patients suffering from nafld, with normal or slightly increased liver enzymes 128
Which inflammatory marker, between systemic immune-inflammation index and neutrophil to eosinophil ratio, is associated with Peyronie's disease and are there any implications for a better understanding of its mechanisms? 125
From bed to bench: which attitude towards the laboratory liver tests should health care practitioners strike? 124
Basal metabolic rate in morbidly obese patients with non-alcoholic fatty liver disease. 124
Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire 123
Abnormally high resistive index of central retinal artery by ultrasound color Doppler in patients with viral chronic liver disease: correlation with worsening liver staging. 123
Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review 122
Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study 122
Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection. 122
What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis? 122
Successful and safe long-term standard antiviral therapy in a patient with “Explosive” immune response in course of HCV-related liver cirrhosis 121
Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome. 119
Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. 119
Could inflammatory markers help diagnose nonalcoholic steatohepatitis? 119
Could the depression of obese patients suffering from chronic hepatitis C be temporarily improved? 118
Epatopatia e coagulazione 117
Drug-induced liver injury due to "natural products" used for weight loss: a case report. 117
Hepatic steatosis, carotid plaques and achieving MDA in psoriaticarthritis patients starting TNF-alpha blockers treatment: a prospective study. 117
Comparison of the everolimus concentrations measured in whole blood with everolimus QMS or sirolimus CMIA 117
Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophilic patients with HCV-related chronic hepatitis? 116
What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? 116
Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. 113
Aspetti psico-sociali delle malattie allergiche 113
Adherence to the Mediterranean Diet and Circulating Levels of Sirtuin 4 in Obese Patients: A Novel Association 113
Extensive psoriasis induced by pegylated interferon: a case report. 112
Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy. 112
UCP1 -3826 AG+GG genotypes, adiponectin, and leptin/adiponectin ratio in severe obesity. 112
Enhanced serum concentrations of transfroming growth factor-beta 1 in simple fatty liver: it is really benign? 111
Is serum Interleukin-17 associated with early atherosclerosis in obese patients? 111
Silent non-alcoholic fatty liver disease - A clinical-histological study 109
Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. 109
Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist? 108
Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis 108
Successful lamivudine monotherapy in an elderly patient suffering from HBV-related decompensated cirrhosis associated with widespread leukocytoclastic vasculitis. 107
Carotid intima-media thickness is predicted by combined eotaxin levels and severity of hepatic steatosis at ultrasonography in obese patients with nonalcoholic fatty liver disease 107
Exposure to ambient air particulate matter and non-alcoholic fatty liver disease 106
What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? 105
Rheumatoid factor after antiviral therapy in patients with HCV chronic hepatitis. 102
Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms 102
Should octreotide be used cautiously in liver cirrhosis with concomitant congestive heart failure correlated to coronary artery disease? 101
What non-alcoholic fatty liver disease has got to do with obstructive sleep apnoea syndrome and viceversa? 101
Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion? 100
Utility of sonography in diagnosing hepatocellular carcinoma 99
Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? 98
Could quantitative liver function tests gain wide acceptance among hepatologists? 98
Noninvasive assessment of liver fibrosis in patients with chronic hepatitis C (and congenital bleeding disorders): where do we stand? 98
Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? 98
Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis 95
Circulating levels of interferon-gamma in course of hepatitis C virus-related arthritis. 95
Analysis of extracellular superoxide dismutase in fibroblasts from patients with systemic sclerosis 95
Inhibition of the mTOR pathway: A possible protective role in coronary artery disease 95
Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity? 94
Liver-spleen axis: Intersection between immunity, infections and metabolism 94
Relationship between growth hormone (GH)/insulin-like growth factor (IGF)-1 status and hepatic steatosis in overweight-obese women. 93
Hepatic steatosis in overweight/obese females: new screening method for those at risk 92
Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. 87
Non-alcoholic fatty liver disease, obesity and other illnesses. 87
Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation 87
Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease 87
Should visceral fat be reduced to increase longevity? 86
Findings from studies are congruent with obesity having a viral origin, but what about obesity-related nafld? 86
A Life-Threating Postpartum Atypical Hemolytic-Uremic Syndrome with Multiorgan Involvement 84
Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. 82
Nutrition, inflammation and liver-spleen axis 80
Pathogenesis of hepatic steatosis: The link between hypercortisolism and non-alcoholic fatty liver disease 79
Does spleen volume play a role in patients with HCV-related chronic hepatitis? 76
Serum 25-Hydroxyvitamin D Levels, Phosphoprotein Enriched in Diabetes Gene Product (PED/PEA-15) and Leptin-to-Adiponectin Ratio in Women with PCOS. 75
Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance 74
Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease 74
Is there a direct role of hepatitis C virus in portosystemic encephalopathy? 70
Positivity for anti-HCV antibodies among Italian hospitalized patients 69
Is the quality of life always depressed in patients with chronic hepatitis C on antiviral therapy? 69
Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism 69
Mammalian Target of Rapamycin in Inflammatory Skin Conditions 69
Steatosis, steatohepatitis and cancer immunotherapy: An intricate story 69
Totale 11.201
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.576
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.576
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202145 0 0 0 0 0 0 0 0 0 0 0 45
2021/2022610 3 1 7 1 4 23 7 22 102 24 154 262
2022/2023785 124 69 30 39 77 76 1 67 117 121 46 18
2023/2024535 25 106 78 33 20 22 10 49 5 12 111 64
2024/20253.373 187 204 12 34 82 220 326 225 190 345 1.265 283
2025/20266.494 691 437 721 670 1.097 277 744 399 792 411 179 76
Totale 12.852